FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3144030288> ?p ?o ?g. }

• W3144030288 endingPage "4023" @default.
• W3144030288 startingPage "4023" @default.
• W3144030288 abstract "Abstract INTRODUCTION: Immature myeloid (IM) cells have been shown to induce immune dysfunction(s) in non-Hodgkin's lymphoma (NHL) patients. Myeloid derived suppressor cells (MDSCs) are a subset of IM cells that play a key role in immune suppression associated with malignancies. In solid tumors, MDSCs have been implicated in promoting angiogenesis, tumor cell invasion and metastasis. The presence of MDSCs may correlate with decreased efficacy of immunotherapies. MDSCs have been associated with reduced survival in solid tumors. We aimed at identifying the patterns of immature myeloid cell subsets including MDSCs in DLBCL patients, pre and post-standard R-CHOP or R-EPOCH therapy. METHODS: Peripheral blood was collected on 31 patients with de novo diffuse large B cell lymphoma on an IRB approved study before and after frontline chemo-immunotherapy and at the time of relapse. Clinical variables at diagnosis (age, performance status, stage of the disease, number of extra nodal lesions) were obtained to calculate prognostic indices (IPI and R-IPI). Cell of origin was determined by IHC using the Hans algorithm. Response to therapy was assessed as per the Lugano criteria for response and assessment in lymphoma. Peripheral distribution of myeloid cells (CD11b+ CD33+), IM cells (HLA-DR-/low IL-4R+) and immunosuppressive IM cell subsets [CD14+ monocytic (m) and CD15+ granulocytic (g) myeloid-derived suppressor cells (MDSCs)] in fresh whole blood samples were established by flow cytometry. RESULTS: Median age was 65 years (range 24-88). Twenty-two (70.9%) patients had stage III/IV disease. Thirteen patients (41.9%) had GCB subtype, 16 patients (51.6%) had non-GCB subtype and cell of origin could not be determined in 2 patients (6.5%). Nineteen patients (61.3%) had IPI scores 0-2 and 12 (38.7%) patients had IPI scores of 3-5. Twenty-two patients (70.9%) received R-CHOP or R-mini CHOP, and 9 patients (29%) received R-EPOCH. The end of therapy ORR and CR were 100% and 96.7% respectively. One patient had a PR. Median follow up was 17.5 months. Two patients (6.4%) subsequently progressed. Both are alive after subsequent therapy. The overall survival is 100%. Prior to treatment initiation, patients presented with 0.23±0.05% circulating IM cells, of which 51.6±5.6% were mMDSC and 11.2±4.4% were gMDSC. No correlation between IM cell distribution (including MDSCs) and IPI or disease stage was observed. A trend was observed towards higher mMDSCs in GCB subtype compared to non-GCB subtype (3.49±1.4% vs. 1.44±0.7% of total myeloid cells; p=0.086). Following treatment with chemo-immunotherapy, overall distribution of circulating IM cells decreased to 0.05±0.04% of total WBC (p=0.012 compared with baseline), 31.2±5.6% of which were mMDSC and 21.3±3.7% were gMDSC. Normalization of IM cell distribution was independent of chemo-immunotherapy regimen or IPI. Compared to early stage disease (I/II), patients with advanced stage disease (stage III/IV) tended to retain more IM cells at the end of therapy (0.06±0.03 vs. 0.03±0.03% of total WBC; p=0.069), a significant proportion of which are mMDSC (0.36±0.25 vs. 0.25±0.07% of total myeloid cells; p=0.032). The two patients who relapsed after initial therapy displayed high proportions of MDSCs among total IM cells throughout the course of their disease compared with non-relapsing patients: at baseline (84.8-97.7% vs. 62.2±4.9% of total IM cells), post treatment (87.7-95.7% vs. 52.5±4.4% of total IM cells). This trend was conserved upon relapse with MDCSs representing 91-93% of total IM cells. CONCLUSIONS: To the best of our knowledge, this is the first study to prospectively examine immature myeloid cells and MDSCs in DLBCL at diagnosis, end of therapy and at the time of relapse. Circulating MDSCs, are associated with an active state of DLBCL. Response to chemo-immunotherapy was associated with a dramatic decrease of circulating IM cells, including MDSCs. Patients with advanced stage disease retained a higher titer of circulating mMDSC at end of therapy. For patients who relapsed, a disproportionate abundance of MDSCs (>85% of total IM cells) were seen at diagnosis, post treatment and at the time of relapse. Taken together, MDSCs may represent a potential biomarker and therapeutic target for relapsed and refractory DLBCL patients. Download : Download high-res image (48KB) Download : Download full-size image Disclosures Park: Teva: Consultancy, Research Funding; Takeda: Research Funding; Cornerstone Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Gilead: Speakers Bureau; Seattle Genetics: Research Funding. Ghosh: Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Seattle Genetics: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Speakers Bureau; Jassen: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding, Speakers Bureau; TG Therapeutics: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Kite Pharma: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Speakers Bureau." @default.
• W3144030288 created "2021-04-13" @default.
• W3144030288 creator A5018065917 @default.
• W3144030288 creator A5025851882 @default.
• W3144030288 creator A5035890812 @default.
• W3144030288 creator A5051183306 @default.
• W3144030288 creator A5063531559 @default.
• W3144030288 creator A5065575770 @default.
• W3144030288 creator A5069014112 @default.
• W3144030288 creator A5069673223 @default.
• W3144030288 creator A5070252326 @default.
• W3144030288 creator A5074766331 @default.
• W3144030288 date "2017-12-07" @default.
• W3144030288 modified "2023-09-28" @default.
• W3144030288 title "Correlation of Myeloid Derived Suppressor Cells and Response to Standard Chemoimmunotherapy in Diffuse Large B Cell Lymphoma" @default.
• W3144030288 doi "https://doi.org/10.1182/blood.v130.suppl_1.4023.4023" @default.
• W3144030288 hasPublicationYear "2017" @default.
• W3144030288 type Work @default.
• W3144030288 sameAs 3144030288 @default.
• W3144030288 citedByCount "0" @default.
• W3144030288 crossrefType "journal-article" @default.
• W3144030288 hasAuthorship W3144030288A5018065917 @default.
• W3144030288 hasAuthorship W3144030288A5025851882 @default.
• W3144030288 hasAuthorship W3144030288A5035890812 @default.
• W3144030288 hasAuthorship W3144030288A5051183306 @default.
• W3144030288 hasAuthorship W3144030288A5063531559 @default.
• W3144030288 hasAuthorship W3144030288A5065575770 @default.
• W3144030288 hasAuthorship W3144030288A5069014112 @default.
• W3144030288 hasAuthorship W3144030288A5069673223 @default.
• W3144030288 hasAuthorship W3144030288A5070252326 @default.
• W3144030288 hasAuthorship W3144030288A5074766331 @default.
• W3144030288 hasConcept C10205521 @default.
• W3144030288 hasConcept C121608353 @default.
• W3144030288 hasConcept C126322002 @default.
• W3144030288 hasConcept C143998085 @default.
• W3144030288 hasConcept C176290653 @default.
• W3144030288 hasConcept C179185449 @default.
• W3144030288 hasConcept C203014093 @default.
• W3144030288 hasConcept C2777701055 @default.
• W3144030288 hasConcept C2779282312 @default.
• W3144030288 hasConcept C2779338263 @default.
• W3144030288 hasConcept C2780653079 @default.
• W3144030288 hasConcept C2780790343 @default.
• W3144030288 hasConcept C28328180 @default.
• W3144030288 hasConcept C502942594 @default.
• W3144030288 hasConcept C54355233 @default.
• W3144030288 hasConcept C55721878 @default.
• W3144030288 hasConcept C71924100 @default.
• W3144030288 hasConcept C86803240 @default.
• W3144030288 hasConcept C8891405 @default.
• W3144030288 hasConceptScore W3144030288C10205521 @default.
• W3144030288 hasConceptScore W3144030288C121608353 @default.
• W3144030288 hasConceptScore W3144030288C126322002 @default.
• W3144030288 hasConceptScore W3144030288C143998085 @default.
• W3144030288 hasConceptScore W3144030288C176290653 @default.
• W3144030288 hasConceptScore W3144030288C179185449 @default.
• W3144030288 hasConceptScore W3144030288C203014093 @default.
• W3144030288 hasConceptScore W3144030288C2777701055 @default.
• W3144030288 hasConceptScore W3144030288C2779282312 @default.
• W3144030288 hasConceptScore W3144030288C2779338263 @default.
• W3144030288 hasConceptScore W3144030288C2780653079 @default.
• W3144030288 hasConceptScore W3144030288C2780790343 @default.
• W3144030288 hasConceptScore W3144030288C28328180 @default.
• W3144030288 hasConceptScore W3144030288C502942594 @default.
• W3144030288 hasConceptScore W3144030288C54355233 @default.
• W3144030288 hasConceptScore W3144030288C55721878 @default.
• W3144030288 hasConceptScore W3144030288C71924100 @default.
• W3144030288 hasConceptScore W3144030288C86803240 @default.
• W3144030288 hasConceptScore W3144030288C8891405 @default.
• W3144030288 hasLocation W31440302881 @default.
• W3144030288 hasOpenAccess W3144030288 @default.
• W3144030288 hasPrimaryLocation W31440302881 @default.
• W3144030288 hasRelatedWork W1475237554 @default.
• W3144030288 hasRelatedWork W18488647 @default.
• W3144030288 hasRelatedWork W2550354355 @default.
• W3144030288 hasRelatedWork W2586126825 @default.
• W3144030288 hasRelatedWork W2587352117 @default.
• W3144030288 hasRelatedWork W2619773935 @default.
• W3144030288 hasRelatedWork W2778897040 @default.
• W3144030288 hasRelatedWork W2907895626 @default.
• W3144030288 hasRelatedWork W2922192036 @default.
• W3144030288 hasRelatedWork W2977293707 @default.
• W3144030288 hasRelatedWork W2977664574 @default.
• W3144030288 hasRelatedWork W2979495513 @default.
• W3144030288 hasRelatedWork W2979563500 @default.
• W3144030288 hasRelatedWork W2984992934 @default.
• W3144030288 hasRelatedWork W2985447369 @default.
• W3144030288 hasRelatedWork W2987297392 @default.
• W3144030288 hasRelatedWork W2988237730 @default.
• W3144030288 hasRelatedWork W2990521001 @default.
• W3144030288 hasRelatedWork W2992045034 @default.
• W3144030288 hasRelatedWork W3108364201 @default.
• W3144030288 hasVolume "130" @default.
• W3144030288 isParatext "false" @default.
• W3144030288 isRetracted "false" @default.
• W3144030288 magId "3144030288" @default.
• W3144030288 workType "article" @default.